Cargando…

Prospects of adjuvant RANKL inhibition in breast cancer?

Detalles Bibliográficos
Autores principales:	Rachner, T D, Wimberger, P, Hofbauer, L C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	News and Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670936/ https://www.ncbi.nlm.nih.gov/pubmed/26583323 http://dx.doi.org/10.1038/cddis.2015.332

Ejemplares similares

RANKL/OPG in Breast Cancer — Extending Its Territory to BRCA Mutation Carriers
por: Rachner, Tilman D., et al.
Publicado: (2015)

From bone to breast and back - the bone cytokine RANKL and breast cancer
por: Hofbauer, Lorenz C, et al.
Publicado: (2011)

Fatal attraction: why breast cancer cells home to bone
por: Hofbauer, Lorenz C, et al.
Publicado: (2008)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

Regulation of VEGF by mevalonate pathway inhibition in breast cancer
por: Rachner, Tilman D., et al.
Publicado: (2013)

New light on Smac mimetics and breast cancer
por: Cornmark, L, et al.
Publicado: (2016)

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin
por: Benad-Mehner, Peggy, et al.
Publicado: (2013)

Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis
por: Klotz, Daniel Martin, et al.
Publicado: (2022)

Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells
por: Göbel, Andy, et al.
Publicado: (2019)

Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
por: Wilke, Maria, et al.
Publicado: (2014)

Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
por: Göbel, Andy, et al.
Publicado: (2020)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
por: Munster, Pamela N, et al.
Publicado: (2001)

The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone
por: Göbel, Andy, et al.
Publicado: (2021)

Novel β-carbolines inhibit Wnt/β-catenin signaling
por: Kong, L, et al.
Publicado: (2015)

Should all adjuvant breast cancer patients receive a bisphosphonate?
por: Cameron, David A
Publicado: (2003)

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer
por: Okines, Dr Alicia FC, et al.
Publicado: (2021)

Engineering adjuvants for predictable immunity
por: Reed, Steven G.
Publicado: (2014)

Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy
por: Alexandrova, Evguenia M, et al.
Publicado: (2017)

Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL
por: Jang, Yuria, et al.
Publicado: (2021)

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response
por: Botta, C, et al.
Publicado: (2016)

Reactivation of p53 via MDM2 inhibition
por: Kim, E S, et al.
Publicado: (2015)

Preventing ototoxic hearing loss by inhibiting histone deacetylases
por: Layman, W S, et al.
Publicado: (2015)

Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies
por: Todenhöfer, Tilman, et al.
Publicado: (2015)

The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor–Positive Breast Cancer
por: Lohmann, Ana Elisa, et al.
Publicado: (2022)

Gluconeogenesis combats cancer: opening new doors in cancer biology
por: Khan, M W, et al.
Publicado: (2015)

Caspase 8 expression may determine the survival of women with ovarian cancer
por: Kim, M, et al.
Publicado: (2016)

SAG-UPS regulates malignant transformation—from chronic inflammation to pro-tumorigenesis to liver cancer
por: Chang, S C, et al.
Publicado: (2015)

Pulmonary sarcomatoid carcinoma: Future prospects of adjuvant immunotherapy in advanced management
por: Agrawal, Anand
Publicado: (2020)

A critical relationship between bone and fat: the role of bone marrow adipose‐derived RANKL in bone metabolism
por: Onji, Masahiro, et al.
Publicado: (2021)

Allelic imbalance in human breast cancer
por: French, Juliet D., et al.
Publicado: (2017)

Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer
por: Browne, Andrew J., et al.
Publicado: (2017)

p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells
por: Browne, A J, et al.
Publicado: (2016)

Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling
por: Condon, Stephen M
Publicado: (2016)

Role of RANKL inhibition in osteoporosis
por: McClung, Michael
Publicado: (2007)

αTAT1: a potential therapeutic target in cancer?
por: Chien, J-Y, et al.
Publicado: (2016)

p53-guided response to nucleostemin loss in normal versus cancer cells
por: Tsai, R Y L
Publicado: (2015)

Histamine: a potential cytoprotective agent to improve cancer therapy?
por: Martinel Lamas, D J, et al.
Publicado: (2015)

First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer
por: Besbes, S, et al.
Publicado: (2015)

RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway
por: Park, Mineon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gblcqea8qa44ts6jf9gm0dqn6f